Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.78 |
| ▸ | TAF1 | P21675 | 1/20 | 0.61 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833797 | 0.93 | BRD4 (0.79) | BRD4TAF1TAF1LADRA1BHDAC4 | |
| SCHEMBL16424682 | 0.88 | BRD4 (1.00) | BRD4TAF1TAF1LADRA1BHDAC4 | |
| SCHEMBL16424671 | 0.87 | BRD4 (1.00) | BRD4TAF1TAF1L | |
| SCHEMBL16424672 | 0.80 | BRD4 (1.00) | BRD4TAF1TAF1L | |
| SCHEMBL17833800 | 0.79 | BRD4 (0.78) | BRD4TAF1TAF1LCREBBP | |
| SCHEMBL17833801 | 0.79 | BRD4 (0.77) | BRD4TAF1TAF1LADRA1BHDAC4 | |
| SCHEMBL20286083 | 0.76 | BRD4 (0.60) | BRD4TAF1TAF1LADRA1BHDAC4 | |
| SCHEMBL16424677 | 0.76 | BRD4 (1.00) | BRD4TAF1TAF1L | |
| SCHEMBL25416714 | 0.74 | ADRA1B (0.91) | BRD4ADRA1BHDAC4HDAC7HDAC9 | |
| SCHEMBL6643651 | 0.74 | ADRA1B (0.67) | BRD4ADRA1BHDAC4HDAC7HDAC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9975896-B2 | Inhibitors of transcription factors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160168154-A1 | INHIBITORS OF TRANSCRIPTION FACTORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168154-A1 | INHIBITORS OF TRANSCRIPTION FACTORS AND USES THEREOF | BRD4, BRPF3, EP300 | BRD4 1/4885TAF1 72/4885TAF1L 33/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | BRD4 205/4885TAF1 75/4885TAF1L 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.